Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.96
  • Today's Change0.001 / 0.06%
  • Shares traded3.81k
  • 1 Year change-32.37%
  • Beta0.8378
Data delayed at least 15 minutes, as of May 21 2024 19:34 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

  • Revenue in USD (TTM)82.31k
  • Net income in USD-8.19m
  • Incorporated1997
  • Employees11.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nascent Biotech Inc0.00-2.09m16.80m----550.02-----0.0147-0.01470.000.00020.00-------346.80-815.53-----------548.75----0.8045---100.00---495.46------
Aytu Biopharma Inc93.76m-13.68m17.15m150.00--0.5572--0.1829-2.65-2.6518.215.530.67922.422.93625,053.30-9.91-33.56-25.58-52.8165.3256.89-14.60-73.810.69230.2160.352--11.1096.5684.33------
Senti Biosciences Inc1.28m-86.11m17.16m48.00--0.3056--13.46-1.93-1.440.02851.230.0097--2.9426,562.50-65.33---71.42-------6,753.80------0.0018---40.25---67.94------
Galecto Inc0.00-30.83m17.24m13.00--0.6123-----1.15-1.150.001.040.00----0.00-63.50-48.46-78.33-52.36------------0.00------37.77------
Minerva Neurosciences Inc0.00-31.60m17.34m9.00---------4.48-4.480.00-5.230.00----0.00-61.90-49.89-65.32-52.39-------442.65------------6.55------
Alterity Therapeutics Ltd (ADR)82.31k-8.19m17.55m11.00--0.7791--213.22-1.98-1.980.022.520.0044--1.527,482.77-44.20-53.02-53.57-61.96-----9,947.97-40,995.62----0.0143--557.60-39.40-7.47---34.88--
Alaunos Therapeutics Inc6.00k-26.77m17.77m1.00--3.71--2,962.31-1.67-1.670.00040.29960.0002--12.006,000.00-97.94-74.83-147.22-89.57-----446,233.30-10,508.06---19.250.00---99.83-49.086.86---15.56--
Pharmacyte Biotech Inc0.00-14.82m18.09m2.00--0.5812-----1.64-1.640.005.740.00----0.00-1.53-13.35-1.62-13.70------------0.00-------1.81------
Tonix Pharmaceuticals Holding Corp10.25m-98.59m18.15m103.00--0.1295--1.77-5.54-5.540.29561.470.0652----99,514.56-62.71-59.46-70.20-65.9237.55---961.87-5,126.730.8666--0.0767------0.1874--320.57--
VBI Vaccines Inc9.41m-83.99m18.32m131.00------1.95-6.93-6.930.4818-0.21660.09231.4037.0571,839.70-81.40-46.58-171.57-58.62-24.06-277.46-881.79-2,755.980.2116-1.601.13--702.4020.9417.18---32.07--
Talphera Inc651.00k-14.31m18.35m15.00--1.12--28.19-0.8945-0.88630.03680.96120.0237----43,400.00-51.96-22.60-67.70-28.55-----2,197.39-714.87----0.00-----21.26-119.16---34.33--
Ibio Inc50.00k-17.13m18.54m26.00--0.7365--370.82-13.10-17.090.02622.920.0011--0.00651,923.08-36.24-28.09-67.39-32.63-----34,258.00-1,467.30----0.3666---100.00--0.9764--42.90--
GlycoMimetics Inc10.00k-37.28m18.62m35.00--0.644--1,862.38-0.5791-0.57910.00020.44860.0002--0.0581285.71-72.29-43.60-81.84-47.82-----372,767.40-2,243.52----0.00---86.67--20.97---29.82--
Allied Corp21.51k-9.00m18.62m--------865.82-0.0915-0.09150.0002-0.07110.00511.650.1441---214.39-------6,919.57---41,861.41--0.0333-31.86-----56.46--31.30------
Raphael Pharmaceutical Inc0.00-1.57m18.66m0.00---------0.0929-0.09290.00-0.00550.00-------624.25-----------------173.44--------61.76------
KALA BIO Inc0.00-39.55m18.67m43.00--2.80-----15.15-15.150.002.370.00----0.00-63.15-57.83-76.71-69.32--57.06---1,553.61---12.260.8382---100.00--5.85---17.31--
Data as of May 21 2024. Currency figures normalised to Alterity Therapeutics Ltd's reporting currency: US Dollar USD

Institutional shareholders

1.20%Per cent of shares held by top holders
HolderShares% Held
Morgan Stanley & Co. LLCas of 31 Mar 202451.94k0.59%
Citadel Securities LLCas of 31 Mar 202418.28k0.21%
XTX Markets LLCas of 31 Mar 202417.43k0.20%
Virtu Americas LLCas of 31 Dec 202310.80k0.12%
Twin Lakes Capital Management LLCas of 31 Mar 20245.93k0.07%
Providence Capital Advisors LLCas of 31 Mar 2024200.000.00%
Osaic Wealth, Inc. (Investment Management)as of 31 Mar 202481.000.00%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 202450.000.00%
FSC Securities Corp.as of 30 Sep 202347.000.00%
Sugarloaf Wealth Management LLCas of 31 Mar 202433.000.00%
More ▼
Data from 30 Sep 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.